Page 56 - Read Online

Page 10 of 11 Tanasanvimon. J Cancer Metastasis Treat 2018;4:57 I http://dx.doi.org/10.20517/2394-4722.2018.38

37. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, et al. Amphiregulin and epiregulin mRNA expression in primary tumors
predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74.
38. Jing C, Jin YH, You Z, Qiong Q, Jun Z. Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer
patients. Oncotarget 2016;7:55890-9.
39. Jonker DJ, Karapetis CS, Harbison C, O’Callaghan CJ, Tu D, et al. Epiregulin gene expression as a biomarker of benefit from cetuximab in
the treatment of advanced colorectal cancer. Br J Cancer 2014;110:648-55.
40. Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, et al. Combined epiregulin and amphiregulin expression levels as a predictive
biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type advanced colorectal cancer. JAMA Oncol
201610.1001/jamaoncol.2015.6065.
41. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, et al. Mismatch repair status and BRAF mutation status in metastatic
colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:5322-30.
42. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results
of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
43. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol
2005;23:609-18.
44. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res
2005;11:8332-40.
45. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, et al. Microsatellite instability does not predict the efficacy of chemotherapy
in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 2009;29:1615-20.
46. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med 2012;366:2443-54.
47. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in
refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
48. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med
2015;372:2509-20.
49. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA
mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773-9.
50. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated
with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol
2016;29:1104-12.
51. Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in
colorectal carcinoma. Mod Pathol 2016;29:1433-42.
52. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common
cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014;23:2965-70.
53. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal
cancer. Eur J Cancer 2013;49:2233-42.
54. Wang HB, Yao H, Li CS, Liang LX, Zhang Y, et al. Rise of PD-L1 expression during metastasis of colorectal cancer: implications for
immunotherapy. J Dig Dis 2017;18:574-81.
55. Lim YJ, Koh J, Kim S, Jeon SR, Chie EK, et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8(+) tumor-
infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol
Phys 2017;99:1216-24.
56. George TJ, Frampton GM, Sun J, Gowen K, Kennedy M, et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy
in colorectal cancer. J Clin Oncol 2016;34:abstr3587.
57. Ali SM, Gay LM, Elvin JA, Vergilio J, Ramkissoon SH, et al. MSI-high and MSI-stable colorectal carcinomas (CRC): a comprehensive
genomic profiling (CGP) study. J Clin Oncol 2018;36:abstr3574.
58. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread
and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
59. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient
population with the BRAF(V600E) mutation. Int J Cancer 2011;128:2075-84.
60. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
61. Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal
cancer: a systematic review and meta-analysis. Colorectal Dis 2013;15:e711-8.
62. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med 2011;364:2507-16.
63. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-
label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
64. Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated
colorectal cancer. J Clin Oncol 2015;33:4032-8.
65. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N
Engl J Med 2015;373:726-36.
66. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through
feedback activation of EGFR. Nature 2012;483:100-3.
67. Kopetz C, McDonough SL, Morris VK, Lenz HJ, Magliocco AM, et al. Randomized trial of irinotecan and cetuximab with or without
vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017;35;abstr520.